The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/87858
Title:
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.
Authors:
Dowsett, Mitch; Tobias, J S; Howell, Anthony ( 0000-0002-3879-5991 ) ; Blackman, G M; Welch, H; King, N; Ponzone, R; Von Euler, M; Baum, M
Abstract:
Thirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial. The primary aim of the trial was to determine the effect of anastrozole upon tamoxifen pharmacokinetics, with secondary aims of assessing the tolerability of the two drugs in combination and whether or not tamoxifen had any effect upon the oestradiol suppression seen with anastrozole. Patients were randomized to receive either 1 mg anastrozole (16 patients) or matching placebo (18 patients) once daily on a double-blind basis for 28 days. No significant difference (P = 0.919) was observed in serum tamoxifen concentrations between the anastrozole and placebo groups during the trial. The serum concentration of oestradiol was significantly suppressed (P < 0.0001) in patients co-administered anastrozole compared with placebo in the presence of tamoxifen, confirming that anastrozole remained an effective suppressant of oestradiol in the presence of tamoxifen. The combination of tamoxifen and anastrozole was well tolerated, with very little difference in side-effects reported between anastrozole and placebo. In conclusion, the results of this study confirm that anastrozole does not affect the pharmacokinetics of tamoxifen when the two drugs are given in combination to post-menopausal women with early breast cancer. In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen.
Affiliation:
Academic Department of Biochemistry, Royal Marsden Hospital, London, UK.
Citation:
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. 1999, 79 (2):311-5 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Jan-1999
URI:
http://hdl.handle.net/10541/87858
DOI:
10.1038/sj.bjc.6690050
PubMed ID:
9888474
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDowsett, Mitchen
dc.contributor.authorTobias, J Sen
dc.contributor.authorHowell, Anthonyen
dc.contributor.authorBlackman, G Men
dc.contributor.authorWelch, Hen
dc.contributor.authorKing, Nen
dc.contributor.authorPonzone, Ren
dc.contributor.authorVon Euler, Men
dc.contributor.authorBaum, Men
dc.date.accessioned2009-12-14T12:51:35Z-
dc.date.available2009-12-14T12:51:35Z-
dc.date.issued1999-01-
dc.identifier.citationThe effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. 1999, 79 (2):311-5 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid9888474-
dc.identifier.doi10.1038/sj.bjc.6690050-
dc.identifier.urihttp://hdl.handle.net/10541/87858-
dc.description.abstractThirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial. The primary aim of the trial was to determine the effect of anastrozole upon tamoxifen pharmacokinetics, with secondary aims of assessing the tolerability of the two drugs in combination and whether or not tamoxifen had any effect upon the oestradiol suppression seen with anastrozole. Patients were randomized to receive either 1 mg anastrozole (16 patients) or matching placebo (18 patients) once daily on a double-blind basis for 28 days. No significant difference (P = 0.919) was observed in serum tamoxifen concentrations between the anastrozole and placebo groups during the trial. The serum concentration of oestradiol was significantly suppressed (P < 0.0001) in patients co-administered anastrozole compared with placebo in the presence of tamoxifen, confirming that anastrozole remained an effective suppressant of oestradiol in the presence of tamoxifen. The combination of tamoxifen and anastrozole was well tolerated, with very little difference in side-effects reported between anastrozole and placebo. In conclusion, the results of this study confirm that anastrozole does not affect the pharmacokinetics of tamoxifen when the two drugs are given in combination to post-menopausal women with early breast cancer. In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogensen
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDouble-Blind Method-
dc.subject.meshEstrogens-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshNitriles-
dc.subject.meshPostmenopause-
dc.subject.meshTamoxifen-
dc.subject.meshTriazoles-
dc.titleThe effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.en
dc.typeArticleen
dc.contributor.departmentAcademic Department of Biochemistry, Royal Marsden Hospital, London, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.